Reimbursement Challenges and Solutions with Molecular Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Dr. Palmer describes how the direct relationship between treatment directed to change in the DNA actually affects the outcome of patients.
Dr. Mauro addresses the debate over selecting first line therapy with three approved agents available.